• Massimo Franchini, Giancarlo Maria Liumbruno, and Mario Pezzo.
• Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantova, Italy.
• Eur. J. Haematol. 2021 Aug 1; 107 (2): 173-180.

AbstractVery rare cases of thrombosis associated with thrombocytopenia have occurred following the vaccination with AstraZeneca COVID-19 vaccine. The aim of this concise review is to summarize the current knowledge on the epidemiologic and pathogenic mechanisms of this syndrome named vaccine-associated immune thrombosis and thrombocytopenia (VITT). A practical patient management section will also be dealt with using information available from national and international scientific societies as well as expert panels. A literature search on the VITT syndrome was carried out in PubMed using appropriate MeSH headings. Overall, 40 VITT cases have been reported. Continuous pharmacovigilance monitoring is needed to collect more data on the real incidence and the pathogenesis of VITT syndrome. Such information will also help us to optimize the management this rare but often clinically severe thrombotic condition associated with COVID-19 vaccination.© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

33 keywords...

hide…